ASH

Key takeaways Primary endpoint not met, but promising trends observed – The Galleri® test did not achieve a statistically significant reduction in combined Stage III–IV cancer diagnoses, but showed favourable shifts toward earlier detection in 12 high-risk cancers. Reduction in late-stage ...

In the randomized phase II PARADIGM trial, azacitidine plus venetoclax outperformed intensive chemotherapy in fit patients with newly diagnosed AML, improving event-free survival and response rates while reducing hospitalization and symptom burden. Patients receiving aza-ven were more likely to proceed to transplant and reported better quality of life, supporting its potential role as an alternative frontline strategy.

The FDA has awarded orphan drug designation to zavabresib for myelofibrosis, recognizing early clinical evidence of meaningful spleen size reduction and a manageable safety profile in combination with ruxolitinib. Interim data show durable responses in a subset of patients who had inadequate benefit from ruxolitinib alone, setting the stage for further development of this investigational bromodomain and extra-terminal (BET) inhibitor in advanced myelofibrosis treatment.

Three experts discuss latest data from IMS and ASH 2025 on BCMA-directed agents for multiple myeloma.

As 2025 draws to a close, we’re celebrating another remarkable year of growth, collaboration and innovation at touchHAEMATOLOGY. From thought-provoking expert interviews and peer-reviewed research to dynamic conference coverage and an expanding portfolio of medical education, this year has been defined by meaningful conversations and impactful learning. We’ve had the privilege of engaging with leading clinicians, researchers and partner societies across the globe - bringing together diverse voices to support the haematology community with timely, accessible and authoritative content. As we reflect on the past 12 months, we’re proud to highlight the moments, milestones and stories that shaped our year.

2025 has brought exciting developments in haematology, with groundbreaking research and real-world progress showcased at EHA, ASH, EBMT and many more leading conferences around the world. We asked our key faculty to share what they believe has been most impactful so far this year – here’s what they told us.

The 67th ASH Annual Meeting and Exposition brought over 30,000+ attendees, 5,000+ novel abstracts and 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups. The meeting highlighted innovations ranging from novel agents to real-world evidence and patient-centred care. In this article, hear from the experts on the key breakthroughs and clinical insights set to shape the future of haematology practice.

Discover the practice-changing data shaping the future of myeloma, chronic lymphocytic leukemia and small lymphocytic lymphoma. Our ASH25 coverage highlights the pivotal Majestec-3 results, emerging CAR T-cell innovations, and the landmark BRUIN CLL-313 trial poised to redefine first-line therapy. With expert commentary from Prof. Meletios-Athanasios Dimopoulos, this in-depth analysis uncovers what these breakthroughs mean for clinical practice.

Discover how ASH25 is reshaping frontline lymphoma care, particularly for older and frail patients. From chemolight combinations to the growing role of bispecific antibodies, Dr Tycel Phillips highlights the five key abstracts poised to influence clinical decision-making.